An update on cladribine for relapsing-remitting multiple sclerosis

Trygve Holmøy1*, Øivind Torkildsen2, and Kjell Morten Myhr3

1. Department of Neurology, Akershus University Hospital, Lørenskog Norway and University of Oslo, Norway
2. Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway and Department of Clinical Medicine, University of Bergen, Norway.
3. Department of Clinical Medicine, University of Bergen, Bergen Norway and Department of Neurology, Haukeland University Hospital, Bergen Norway

*Corresponding author:

Trygve Holmøy
Universitetet i Oslo
Lørenskog
Norway
trygve.holmoy@medisin.uio.no

Funding
This paper was not funded

Declaration of interest:
T Holmøy has received speakers honoraria and research grants from Merck, Biogen, Genzyme, Novartis and Teva; speakers honoraria from Santen, and served on advisory board for Genzyme, Merck and Biogen. Ø Torkildsen has served on advisory boards and received travel grants and speakers honoraria form Biogen Idec, Merck and Genzyme, and received speakers honoraria and travel grants from Novartis. K M Myhr has received unrestricted research grants to his institution and scientific advisory board or speakers honoraria from Biogen Novartis, Merck and Teva; speakers honoraria from Amirall; and has participated in clinical trials organized by Biogen, Merck and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Abstract

Introduction. Despite recent progress, currently available therapies for relapsing remitting multiple sclerosis (MS) are only partly effective, and their use is limited by tolerability and safety issues, as well as high cost. Cladribine was originally rejected by the regulatory authorities in both the European Union and USA in 2011, but in June 2017 the European Medical Agency recommended marketing authorization for treatment of aggressive relapsing MS.

Areas covered. We provide an update on chemistry, mechanism of action, efficacy and safety of cladribine for the treatment of MS.

Expert opinion. Cladribine is well tolerated, it is dosed orally in cycles of one year, the need for regular blood testing during treatment is likely limited, and the two-year efficacy data for treatment of relapsing MS are at least in the same range as the most efficient licensed treatments. The increased risk of malignancies reported in the pivotal trial seems to be caused by unexpectedly low numbers of malignancies in the placebo group. Cladribine could therefore be an alternative for many patients with relapsing remitting MS. The main caveat is the lack of long term efficacy and safety data. Currently there are insufficient data to guide further treatment of patients who have completed two treatment cycles of cladribine.

Keywords

Multiple sclerosis, cladribine, treatment, review
1. Introduction

The number of people living with multiple sclerosis (MS) increased from 2.1 million in 2008 to 2.3 million in 2013 [1]. Immunomodulatory drugs are used to prevent relapses and disability progression mainly in the relapsing forms of the disease, and are most effective if started early when the inflammation mediated by migration of lymphocytes across the blood-brain barrier is most pronounced [2]. In these patients, drugs usually dominate cost of illness, whereas informal care and production losses dominate during advanced disease [3]. Drug costs and access to MS treatment is highly variable, and immunomodulatory treatment is still unaffordable for many MS patients, even within the European Union [4].

Cladribine for the treatment of MS was reviewed in 2013 [5], after the drug was rejected by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Merck later filed a new application to EMA based on additional clinical data, and in June 2017 EMA recommended marketing authorization. Another review is therefore relevant.

2. Overview of the market

More than 10 therapies are available for the treatment of relapsing remitting MS (RRMS) [6,7]. There are however, important unmet needs, in particular for those approximately 50% of MS patients having progressive disease forms. The B cell depleting monoclonal antibody ocrelizumab has shown some efficacy also in primary progressive MS [8], and was recently approved as the first treatment for this subtype of MS by FDA. The effect on disease progression was however modest, and so far no drugs are approved for secondary-progressive MS.

For RRMS, drugs with an improved balance between efficacy, side effects and cost are still needed. The injectable drugs interferon beta-1a and -1b, peginterferon beta-1a and glatiramer acetate are safe, but have limited efficacy and are often poorly tolerated [6,7]. The monoclonal antibodies natalizumab, alemtuzumab, daclizumab and ocrelizumab have more pronounced efficacy and are often better tolerated. Their use is, however, restricted by serious adverse effects such as progressive multifocal leukoencephalopathy (PML) for natalizumab [9], secondary autoimmunity and opportunistic infections including fatal cases of listeriosis for alemtuzumab [10,11], and liver damage for daclizumab [12]. Among the oral drugs teriflunomide and dimethyl fumarate have an efficacy that is comparable to the injectables,
whereas fingolimod is more effective [6,7]. The advantage of oral administration is, however, to some extent outweighed by the need for frequent blood sampling, tolerability issues, and for dimethyl fumarate and fingolimod also opportunistic infections, including PML that is possibly related to lymphopenia [13,14]. Most immunomodulatory drugs lose their effect rapidly when stopped, and severe rebound disease activity has been reported for natalizumab and fingolimod [15,16]. MS preferentially affects young women, and none of the drugs can be recommended unconditionally during pregnancy [17]. There is thus a need for drugs with high efficacy, safety and tolerability, and with prolonged clinical effect that can protect women when trying to become pregnant as well as during pregnancy.

For many MS patients across the world an affordable treatment is the most obvious unmet need. The costs of drugs for MS has accelerated more than comparable treatments for other diseases [18]. The introduction of generics has so far not reduced prices substantially, possibly because there are too few generics on the market [19].

2. Introduction to the compound

2.1 Chemistry

Cladribine is a small molecular drug with a molecular weight of 285.687 g/mol and belongs to the group of chemotherapeutic agents known as antimetabolites. The chemical name is 2-chloro-2'-deoxyadenosine (2CdA) (C_{10}H_{12}ClN_{5}O_{3}). It is a purine analogue that mimics the nucleoside adenosine. It is phosphorylated by deoxycytidine kinase to 2-chloro-2'-deoxy-ß-D-adenosine monophosphate (2-CdAMP). CdAMP is resistant to deamination by adenosine deaminase. Since there is little deoxynucleotide deaminase in lymphocytes and monocytes, the metabolite accumulates intracellularly and is converted into the active triphosphate deoxynucleotide,2-chloro-2'-deoxy-ß-D-adenosine triphosphate (2-CdATP), leading to cell death [20].
2.2 Pharmacodynamics

Cladribine differs structurally from deoxyadenosine by the presence of a chlorine atom at position two the purine ring. This results in resistance to degradation by adenosine deaminase and a more prolonged cytotoxic effect against resting and proliferating lymphocytes. Cladribine passively crosses the cell membrane and is phosphorylated by deoxycytidine kinase [21]. The ratio of deoxycytidine kinase to deoxynucleotidase is high in lymphocytes and monocytes, leading to phosphorylation to the active compound triphosphate deoxynucleotide, 2-chlorodeoxyadenosine-ATP. Cells with high levels of deoxynucleotides are unable to repair single-strand DNA breaks, leading to subsequent DNA damage and cell death. Cladribine thus induces a rapid and prolonged decrease in circulating B and CD4+ T-lymphocytes [22,23], including both resting and dividing cells [24]. It was early reported that B cells are particularly sensitive to cladribine [25]. Notably, oral cladribine in doses used in clinical trials suppressed CD19 B cells by 70-90% with repopulation to 15-20% of baseline values before redosing, suppression of CD4 and particularly CD8 T cells were much less pronounced [26,27]. Thus, memory B cells have recently been suggested to be particularly important for disease control in MS, including during treatment with cladribine [26,27]. Because of its cytotoxic effect on lymphocytes, cladribine is used in cancer therapy and is indicated against Hairy Cell Leukemia and B-cell chronic lymphocytic leukemia [28]

It has been suggested that cladribine also exert effects independently of deoxycytidine kinase activity and cell proliferation. Thus, it has been shown in vitro that cladribine exposure may prevent T cell activation and proliferation also in the presence of deoxycytidine, which allows T cells to survive in the presence of cladribine [29]. The clinical importance of this observation is uncertain, particularly as the clinical effect of cladribine (table 1) persists for many months after clearance of the drug [30]. Moreover, in a recent study cladribine did not impair proliferation in surviving mononuclear cells, but rather induced an anti-inflammatory cytokine profile with increased IL4/INF-gamma ratio and a trend towards increased IL-10 production [31].
Although the clinical effects of cladribine are mainly attributed to the effects on lymphocytes, other mechanisms may also operate. It has thus been suggested that induction of interferon alpha producing myeloid dendritic cells could account for some of the effects in MS [23]. In the experimental autoimmune encephalomyelitis (EAE) model of MS cladribine interferes with the synaptic effects of IL-1beta, indicating that it could also have neuroprotective properties independent of its effects on peripheral lymphocytes [32].

2.3 Pharmacokinetics and metabolism

The bioavailability of cladribine is 100% when administered intravenously and 37-51% when given orally [21]. A bioavailability of 45.6% when administered without food and 40.5% when administered with food was recently reported in MS patients. The half-life is 5.7 to 19.4 hours and distribution volume varies from 54 to 357 L/m2. Protein binding is 20% [21]. The concentration in cerebrospinal fluid (CSF) is 25% of that in plasma in patients without central nervous system disease, and exceeds the plasma level in patients with meningeal disease. [21]

About 18% of the administered dose has been reported to be excreted in urine in patients with solid tumors. The major catabolite measured in plasma and urine, 2-chloroadenine, has also been shown to be cytotoxic in vitro, although less so than cladribine [33]. About five times more 2-chloroadenine were measured in urine after oral compared to intravenous administration, and it has been suggested that this metabolite may contribute to the clinical effect after oral administration of cladribine. [33] Renal clearance of cladribine seems to be correlated with creatinine clearance, with a decrease of 19% and 40% in patients with mild and severe renal impairment respectively [34].

3. Clinical efficacy

3.1. Parenteral administration

There has never been a true phase I study of cladribine in MS. Safety and dose finding decisions have been based on studies of patients with malignancies [35,36]. From these studies and previous clinical experiences, Sipe and colleagues initiated a pilot study of four patients with progressive MS with intravenous cladribine in 1990 [36-39].
The results of clinical studies are shown in Table 1. The promising pilot results triggered the first randomized study to evaluate the efficacy and safety in MS in 1992, with 51 patients and crossover design [37,38]. The inclusion criteria were defined as clinically definite or laboratory supported definite MS according to the Poser criteria [40], with chronic progressive disease for more than 2 years [37,40]. The baseline mean EDSS was 4.6 and 4.7, and mean age 42.7 and 43.0 years in the placebo and cladribine group respectively. The authors have later stated that most patients had relapses, and thus secondary progressive MS [36,41]. The study population was matched according to age, sex, and disease severity into pairs of patients, and randomized to receive 4-monthly doses of one week with 0.10 mg/kg/day (a total dose of 2.8 mg/kg) or placebo the first study year. In the second year the original cladribine patients received placebo, and the original placebo patients were crossed over to cladribine 0.10 mg/kg for 7 days in month 1 and 0.05 mg/kg for 7 days during months 2 and 3 (total dose 1.4 mg/kg), followed by 7 days of placebo in month 4. The cladribine dose was thus 50% of that given to the cladribine arm the first year [38,39]. Results from the first year showed highly significant clinical effects of cladribine 2.8 mg/kg as measured by the Scripps Neurologic Rating Scale (SNRS) and the Extended Disability Status Scale (EDSS) scores. Analyses of the patient pairs revealed a treatment effect in favor of cladribine after 12 months as evaluated by both EDSS (p<0,004) and SNRS (p<0.001) [37]. Time to EDSS progression of 1 (p=0.012) or 1.5 (p=0.024) steps, and SNRS progression by a loss of 10 (p=0.004) or 15 (p=0.009) points during the first year was lower in the cladribine arm compared to placebo [39]. The findings were confirmed by reduction of contrast enhancing MRI lesions at month 12 (8 % among the patients in the cladribine arm compared to 50 % in the placebo arm; p<0.001) [39]. The effects on clinical outcomes were less pronounced during the second year at the lower dose of 1.4 mg/kg, possibly indicating a dose-response effect [36,39]. However, there was a highly significant reduction of contrast enhancing MRI lesions from month 12 (50 %) to month 24 (5 %) in the original placebo arm that received cladribine 1.4 mg/kg during the second year. None of the patients who received cladribine 2.8 mg/kg during the first year and placebo the during second year had contrast enhancing lesions at month 24, indicating a prolonged treatment effect [39].

A second phase II randomized, placebo-controlled, double-blind study included 52 patients with RRMS, who either received subcutaneous cladribine 0.07 mg/kg daily (n=27) at 5 consecutive days for 6-monthly courses (total dose 2.1 mg/kg) or placebo (n=25) for 18 months [42]. Patients should have a RRMS diagnosis for at least one year, at least two
relapses the preceding two years prior to inclusion, and a baseline EDSS score ≤ 6.5. Primary outcome measures were combined frequency and severity of relapses after one year, and the number of contrast enhancing MRI lesions at 12 monthly scans. Secondary outcome measures included change in EDSS and SNRS scores, and relapse rate and MRI disease activity after 18 months.

Cladribine treated patients experienced lower number and severity of relapses, with an estimated annual relapse rate from month 6 to month 12 at 0.77 compared to 1.67 in the placebo arm (p=0.021). The difference remained significant at month 18 (0.66 in the cladribine arm compared to 1.34 in the placebo arm; p=0.010). Cladribine treated patients also had fewer contrast enhancing MRI lesions at month 12 compared to the placebo group (p=0.0001). The difference was already present at month 7 (p=0.0001), and remained at month 18 (p=0.002). No differences were detected in the EDSS and SNRS scores [42].

A third cladribine study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group design study that evaluated the safety and efficacy of two subcutaneous cladribine doses in a population of progressive MS patients (70% SPMS and 30 % PPMS) [43]. Altogether 159 patients were included and received in total 0.7 mg/kg (n=53) or 2.1 mg/kg (n=52) cladribine or placebo (n=54). Treatment evaluation was performed after one year and was further planned for a 6-year open-label extension [43]. Patients were aged 21–60 years, had clinically definite or laboratory supported MS according to the Schumacher criteria [44] or Poser criteria [40]. They had a chronic progressive disease, defined as slowly progression of signs and symptoms over the preceding 12 months prior to inclusion, and a baseline EDSS score between 3.0 and 6.5. The primary outcome measure was the mean change in EDSS score from baseline to the final evaluation. Secondary outcome measures included mean change from baseline in SNRS score and time to progression (increase in EDSS score of ≥1.0 step for patients with baseline scores from 3.0 to 5.0 or ≥ 0.5 step for those with baseline scores from 5.5 to 6.5, confirmed at the next scheduled visit). Additional secondary outcome measures included the proportion of patients with contrast-enhanced T1-weighted MRI lesions at the final evaluation, the number and volume of enhanced T1-weighted lesions and volume of T2-weighted lesions.
The results revealed no differences in mean changes of EDSS and SNRS scores during the 12-month double-blind phase of the study. EDSS scores in the SPMS placebo subgroup increased modestly (0.3) compared to stable scores in the SPMS cladribine subgroups, but the difference was not statistically significant. Even smaller differences were found for the PPMS subgroups. A total of 33% of the patients in the SPMS placebo subgroup experienced EDSS progression, compared to 24% and 27% in the SPMS cladribine subgroups (not statistically significant). However, fewer patients had contrast-enhanced T1-weighted MRI lesions at month 12 in the cladribine 2.1 mg/kg arm (6 %; p=0.0017) and the 0.7 mg/kg arm (10 %; p=0.013) compared to placebo (32 %). The mean number and volume of contrast-enhanced T1-weighted MRI lesions were also lower in both cladribine arms at month 12 compared to placebo (p<0.001 for high dose and p≤0.004 for low dose). The mean change in T2 lesion volume from baseline to month 12 was significantly lower in the cladribine high dose arm (p=0.040), but not in the low dose arm (p=0.055) compared to placebo [43].

Subcutaneous cladribine was also studied in a Polish crossover study that included 84 treatment-naive patients with relapsing MS [45]. The patients should have at least one contrast enhancing MRI lesion (timing not specified), EDSS score of 1.0–7.0, and no clinical relapse the last three months. Patients were randomized to receive seven courses of cladribine 5 mg daily for five consecutive days at month 1-6 and at month 9 or placebo the first year, and crossed-over for the same dosing regimen the second year. The mean dose for all patients was 2.45 mg/kg. The results showed a reduction in relapse rate during the first year in the cladribine group, and an improvement in EDSS score that were not sustained throughout the study period of two years. The original placebo group that received cladribine the second year did not experience reduction in relapse rate, but had stable EDSS score. MRI was not included as an efficacy endpoint [45].

3.2. Oral administration
Oral administration of cladribine was studied in the first phase 3 study in RRMS (CLARITY) [30]. This double-blind, multicenter, randomized study randomized 1326 patients to receive either cladribine 5.25 mg/kg (n=456), cladribine 3.5 mg/kg (n=433), or placebo (n=437) for 96 weeks from April 2005 to January 2007. The study medication was administered as four courses (4-5 days) during the first 48 weeks (week 1, 5, 9, and 13), and two courses during the next 48 weeks (week 48 and 52). Patients were aged 18–55 years, with RRMS according to the McDonald criteria [46], MRI lesions consistent with MS [47], at least one relapse during
the 12 months before study entry, EDSS score ≤ 5.5 [40], and normal hematologic status. The primary end point was relapse rate at 96 weeks. Main secondary efficacy endpoints included proportion of relapse free patients, time to 3 months sustained disability progression ≥ 1 EDSS step (≥ 1.5 steps if the baseline EDSS score was 0), mean number of gadolinium-enhancing T1-weighted MRI lesions per patient per scan; active T2-weighted lesions, and combined unique MRI lesions [30]. The results showed that cladribine reduced the annualized relapse rate at week 96 to 0.15 (0.12–0.17) for 5.25 mg/kg and 0.14 (0.12–0.17) for 3.5 mg/kg, compared to 0.33 (0.29–0.38) for placebo, corresponding to 58% and 55% relative reduction respectively (p < 0.001 for both). More patients in the cladribine groups were relapse free (80% for 3.5mg/kg and 79% for 5.25 mg/kg versus 61% for placebo; p < 0.001 for both). The risk for 3-month sustained disability progression was also reduced by about 30% in both cladribine arms (hazard ratio 0.67 [95% CI: 0.48, 0.93; p = 0.018] for 3.5 mg/kg and 0.69 [95% CI: 0.49, 0.96; p = 0.026] for 5.25 mg/kg). Clinical outcomes were confirmed by reductions in MRI activity in both cladribine arms (T1 gadolinium-enhancing lesions 86-88 %, active T2 lesions 73-77 % and combined unique lesions 74-78 %; p < 0.001 for all).

To assess the effect of another two years of oral treatment, an extension phase of the CLARITY study started in February 2008 [48]. After a variable treatment gap (median 40 weeks), patients in the cladribine arms were randomized to further treatment with either cladribine 3.5 mg/kg or placebo, and the original placebo patients received cladribine 3.5 mg/kg for another two years. The results have so far only been presented as abstracts. The annual relapse rate was 0.15 (97.5% CI 0.09-0.21) in patients treated with cladribine 3.5mg/kg in the original study and placebo in the extension study, and 0.10 (97.5% CI 0.06-0.13) in those who received cladribine 3.5mg/kg in both studies (P=0.059) [49]. The MRI findings support that effect of two years treatment is maintained over four years, although some disease activity recurs. Thus, the proportion of patients without gadolinium-enhancing lesions was 85.1-89.9 % in cladribine-treated groups in the extension study versus 73.0-80.2% in placebo-treated groups. The respective proportions without active T2 lesions were 37.6-43.7% and 27.6-34.4%. The mean numbers of new gadolinium-enhancing lesions/subject/scan were lower (0.03±0.08) in patients treated with cladribine 3.5mg/kg in both studies than in those treated with cladribine 3.5mg/kg in CLARITY and placebo in the extension study (0.28±0.87; p<0.001) [50]. As only 284 of the 433 originally cladribine 3.5 mg/kg treated patients were included in the extension study [30,49] the generalizability of the results could be questionable.
The effect on brain atrophy in the CLARITY study was recently reported [51]. To avoid confounding from pseudo atrophy, annualized brain volume change was assessed from months 6 to 24. This was significantly reduced in patients treated with cladribine 3.5 mg/kg (−0.77% ± 0.94%; p = 0.02) and 5.25 mg/kg (−0.77% ± 0.95%; p = 0.02) compared to placebo (−0.95% ± 1.06%)

Oral cladribine was examined in clinically isolated syndrome (CIS) in the ORACLE study [52]. In a double-blind, multicenter, randomized, phase-3 study, 204 patients received oral cladribine 5.25 mg/kg, 206 received oral cladribine 3.5 mg/kg, and 206 received placebo for pre-planned 96 weeks. The study medication was given as four courses (4-5 days) during the first 48 weeks (week 1, 5, 9, and 13) and two courses during the next 48 weeks (week 48, 52). Patients were aged 18–55 years, and had a first clinical demyelinating event within 75 days before screening, at least two clinically silent brain lesions of at least 3 mm on a T2-weighted MRI scan, and an EDSS score ≤ 5.0. A total of 616 patients were included from October 2008 to October 2010. Due to regulatory authorities expression of concern, Merck choose to stop further development of the cladribine-program and initiated early-termination of the study in October 2011, with the last patient visit in April 2012. The primary efficacy endpoint was time to conversion to clinically definite MS (second clinical event) according to the Poser criteria [40]. The main secondary efficacy endpoint was time to conversion to MS according to the 2005 McDonald criteria, meaning the time to a new MRI lesion or a second clinical event [53]. Secondary MRI endpoints included numbers of new or persisting T1 gadolinium-enhancing lesions and new or enlarging T2 lesions. Overall, 363 (59%) patients completed six treatment courses, and at the end of the study 149 (24%) patients had permanently discontinued treatment. The most common reasons for discontinuation were patient’s decision, termination of the trial program, or a Health Authority or sponsor request to stop treatment.

Cladribine significantly delayed the time to conversion to clinically definite MS, with 62% risk reduction for 5.25 mg/kg (HR 0.38; 95% CI 0.25–0.58; p<0.0001) and 67% for 3.5 mg/kg (HR 0.33; 95% CI 0.21–0.51; p<0.0001) versus placebo. Cladribine also significantly reduced conversion to “McDonald MS” versus placebo; with 57% risk reduction for 5.25 mg/kg (HR 0.43; 95% CI 0.33–0.55; p<0.0001), and 50% risk reduction for 3.5 mg/kg (HR 0.50; 95% CI 0.39–0.63; p<0.0001). The cladribine high dose resulted in a 91% risk reduction for new or
persisting T1 gadolinium-enhancing lesions, and 73% for new or enlarging T2 lesions compared to placebo. The low dose resulted in 89% risk reduction new or persisting T1 gadolinium-enhancing lesions and 79% for new or enlarging T2 lesions compared to placebo.

Yet another study (ONWARD) was a phase 2 study of cladribine add-on therapy to IFN-beta [54]. The patients were aged 18 to 65 years and had definite RRMS or SPMS with superimposed relapses according to the revised 2005 McDonald criteria [53]. They should be treated with either of the available IFN-beta formulations (subcutaneous IFN-beta-1a or 1b, intramuscular IFN-beta-1a) and had experienced at least one relapse within 48 weeks prior to screening. The patients were randomized to add-on therapy with oral cladribine for 4-5 consecutive days at weeks 1, 5, 48, and 52 to a total dose of 3.5 mg/kg (n=124) or identical placebo (n=48) tablets during a double blind period of 96 weeks. The results have not been published in a full-length article, but preliminary data indicate lower mean number of relapses in the cladribine 3.5 mg/kg-IFN-beta arm (0.23) compared to the placebo-IFN-beta arm (0.54; p<0.001) [54]. The relapse rate was 0.13 in the cladribine 3.5 mg/kg-IFN-beta arm and 0.32 in the placebo-IFN-beta arm, and the corresponding mean number of T1 gadolinium-enhancing lesions per scan was 0.06 and 0.34 (statistical analyses not available). The frequency of lymphopenia seems to be unacceptable high (grade 3 or 4 lymphocyte toxicity were recorded in 63.7% in the cladribine 3.5 mg/kg-IFN-beta group and 2.1% in the placebo-IFN-beta group).

All patients who participated in one of the oral cladribine trials have been offered participation in a prospective long-term observational safety registry; The PREMIERE (PRospective observational long-term safEty registry of Multiple sclerosis patIEnts who have participated in CladRibinE clinical trials) registry) [55]. The registry started ten years recording in November 2009, and aims to evaluate the long-term safety of oral cladribine in MS. No results have so far been posted.

4.0 Safety and tolerability

4.1. Overview

The tolerability of oral cladribine in doses tested in MS seems to be very good [56]. In CLARITY, 86.6% of the patients in the cladribine groups and 86.3% of the patients in the placebo group completed the study [30]. Among the most common adverse effects, headache,
nausea, urinary tract infection and nasopharyngitis occurred in comparable frequencies in the placebo and cladribine groups. There were four deaths during the CLARITY study and two after study discontinuation, two in each treatment arm. Causes of death were acute myocardial infarction and metastatic pancreatic carcinoma in the cladribine 3.5 mg/kg arm, drowning and cardiopulmonary arrest, secondary to exacerbation of latent tuberculosis in the cladribine 5.25 mg/kg arm, and suicide and hemorrhagic stroke in the placebo arm. No deaths occurred in the ORACLE study [52].

4.2. Lymphopenia

Depletion of T- and B cells is a mechanism of cladribine [24,27]. In CLARITY cladribine rapidly decreased lymphocyte counts, which reached nadir at 3–4 weeks following the first treatment course [30]. Recovery was incomplete at week 48. At week 96 median lymphocyte counts were 56% of baseline values in the 3.5 mg/kg group and 52% in the 5.25 mg/kg groups. Median neutrophil counts at week 96 were 85% and 82% of baseline values in the 3.5 and 5.25 mg/kg groups, respectively. Grade 3 and 4 lymphopenia (<0.5 × 10^9 lymphocytes/l) were recorded in 25.6% patients in the 3.5 mg/kg group and 44.9% of patients in the 5.25 mg/kg group and 0.5% of patients in the placebo group, compatible with a dose-effect response [56]. Accordingly, in ORACLE lymphopenia occurred in 48 (24%) in the high dose, 25 (12%) in the low dose and none in the placebo arm [52], and was reported as a severe event in 10 (5%) patients in the 5.25 mg/kg group and four (2%) patients in the 3.5 mg/kg group. The effect on neutrophils was less pronounced.

4.3. Infections

An increased risk of opportunistic infections is expected from the high risk of pronounced lymphopenia associated with cladribine. Uppsala Monitoring Centre (UMC) has recorded 5 cases of PML associated with cladribine [57]. The reported indications for treatment were Waldenstrøm’s macroglobulinemia (2 cases), hairy cell leukemia, aggressive systemic mastocytosis, and non-hodgkin's lymphoma. No cases of PML have been reported in the MS studies. In CLARITY infections occurred in 48.3% of patients in the cladribine groups compared to 42.5% in the placebo group. The vast majority (99%) of these were graded as mild or moderate [56]. Herpes zoster infections were reported in eight patients in the cladribine 3.5 mg/kg group and 12 patients in the 5.25 mg/kg group, and was inversely correlated with the lymphocyte counts (p=0.003). None herpes zoster infections were reported
in the placebo group. In ORACLE herpes virus infections were reported in 6 % in the high
dose, 8 % in the low dose and 1 % in the placebo arm [52]. All cases of herpes infection in
CLARITY were cutaneous, whereas three cases of systemic herpes zoster infection have been
reported to UMC, again most likely in patients treated for malignancies. Three cases of
tuberculosis are recorded by UMC, and one case of tuberculosis was reported in CLARITY.

4.5. Malignancies

Both interference with DNA repair and reduced tumor surveillance could in theory lead to
increased risk of malignancies during treatment with cladribine. The effect of tumor
surveillance is not routinely addressed in preclinical studies, but has been shown for
fingolimod in a mouse model of myeloma [58]. Long-term mice studies revealed a significant
increase in Harderian gland tumours, including adenocarcinomas. This was not considered
clinically relevant, as humans do not have a comparable anatomical structure [59]. Cladribine
also induced chromosomal effects in an in vivo bone marrow micronucleus assay in mice and
also in an in vitro assay, and was mutagenic in mammalian cells in culture [28].

In CLARITY three malignancies (ovarian carcinoma, pancreatic carcinoma and melanoma)
occurred in the cladribine groups, and none in the placebo groups during the study, and one
case of choriocarcinoma occurred during post trial surveillance. Benign uterine leiomyomas
occurred in 9 women in the cladribine groups and one in the placebo groups [56]. The risk of
cancer (0.34%) was thus significantly higher in the cladribine groups than in the placebo
groups. This was, however, likely driven by the unexpectedly low occurrence of cancers in
the placebo group. A meta-analysis showed that the risk of malignancies in CLARITY was
not different from that in other phase III studies in MS [60]. In ORACLE neoplasms (all
types; benign; malignant; unspecified) occurred in one (<1%) patient in the cladribine 5.25
mg/kg arm, three (1%) in the cladribine 3.5 mg/kg arm, and six (3%) in the placebo arm [52].

5. Fertility and pregnancy
Whereas preclinical studies did not show effects on female fertility, cladribine induced lethal effects in the offspring of female mice at all stages during \textit{in utero} development, and was clearly teratogenic in mice and rabbits [28,59]. The offspring of some male mice had skeletal deformities. EMA concluded that cladribine interferes with spermatogonial cells, implying a minimal risk of inheritable genetic damage after discontinuation of treatment for a period long enough for a new spermatogonetic cycle to achieve completion [59]. The data in humans are restricted to case reports. Pregnancy and lactation should be considered contraindicated during treatment. An official recommendation for the washout period after oral cladribine in doses relevant for MS is pending, but women and men treated with cladribine for malignancies are currently advised not to become pregnant or father a child until six months after the last dosing [28,61-63].

6. Regulatory affairs

Merck applied for market authorization in Europe in and in the United States in 2009 [63], but did not achieve regulatory approval. EMA expressed safety concerns, especially related to malignancies [64]. Moreover, EMA considered the efficacy not sufficiently well established in the subgroup of patients most likely to use cladribine. After the rejection Merck announced in 2011 to no longer pursue the global approval process for cladribine tablets [65]. However, since then more follow-up data on safety and efficacy have been collected through the ORACLE study [52], the Premiere Registry [54], the CLARITY Extension study [48] and meta analyses [60]. Merck submitted in 2016 a new application for marketing authorization for cladribine tablets for the treatment of MS [66]. In June 2017 the Committee for Medicinal Products for Human Use in EMA recommended marketing authorization for patients with highly active relapsing MS as defined by clinical or imaging features [61].

7. Conclusion

The efficacy of cladribine on relapse rate, MRI activity and EDSS progression over two years in RRMS, and the risk of conversion from CIS to RRMS, is well established [30,52]. Cladribine may be regarded as an induction therapy due to prolonged effect after clearance of the drug. The data from extension studies are however limited by risk of attrition bias, and some disease activity seem to recur. Moreover, data on cognition and patient reported outcomes, including fatigue and quality of life, are missing. The risk of serious adverse
events, including malignancies, do not seem to differ substantially from that of other drugs with comparable efficacy [60]. However, as for other immunosuppressive drugs a modest risk associated with prolonged treatment cannot be ruled out.

8. Expert opinion

No evidence of disease activity (NEDA) is an emerging goal in MS treatment [67]. NEDA can be defined in different ways. Including the proportion of patients with no relapses, no EDSS progression over six months (91%), no new gadolinium-enhancing T1-lesions (87%) and no new or enlarging T2 lesions (62%) after two years in CLARITY, the proportion of patients with NEDA at year two was 44% for 3.5 mg/kg and 46% for 5.25 mg/kg [68]. This is in the same range as recently reported with ocrelizumab (47.9% and 47.5% in OPERA I and II at week 96) [69], and possibly higher than for natalizumab (37%) [70], and alemtuzumab (32% in patients who had relapsed on first line treatment) [71]. These numbers must be interpreted carefully, as NEDA does not reflect important aspects such as fatigue, depression, quality of life or brain atrophy [72]. In a two-year perspective, the efficacy of cladribine on routinely used outcome measures does however seem to be at least as good as the licensed monoclonal antibodies, and in the same range as B cell depleting treatment.

Given that several drugs have comparably high efficacy on clinical and radiological outcomes, safety, tolerability and cost may be decisive for the choice of treatment. Of the licensed drugs with comparable efficacy, natalizumab is also well tolerated but is associated with an unacceptably high risk of progressive multifocal leukoencephalopathy in JCV-positive patients, currently estimated to 6.1 per 1000 after 49 – 72 weeks treatment in patients without previous immunosuppression [73]. The risk of secondary autoimmunity associated with alemtuzumab is high [11], and there is also a growing concern regarding opportunistic infections such as cytomegalovirus, nocardiosis and listeriosis [10,74-76]. As many MS patients are fertile women, disease protection during pregnancy and lactation is important in treatment decisions. Women are usually advised to stop immunomodulatory treatment before they conceive [17], and women treated with natalizumab and fingolimod may in such cases experience serious rebound disease activity [15,16]. Cladribine must be regarded as teratogenic and should be avoided the last months prior to and during pregnancy. However,
the sustained immunological effects including prolonged B cell depletion will offer protection against disease activity during pregnancy and lactation after the drug is cleared from the body, and are not likely harmful to the fetus. A reasonable washout period in both men and women treated with oral cladribine for MS needs to be established. Given the short half-life [21], a period of 6 months which is recommended after intravenous administration may be unnecessary long.

There are, however, caveats. Opportunistic infections occur, and as for other treatments leading to lymphopenia, rare cases of PML could also appear in MS patients [14], though the risk should be reasonably small given the minor effect of cladribine on the CD8+ T cell population [27].

Notably, the extension trials should be interpreted carefully due to the risk of attrition bias, and there is at present limited data to guide the treatment after year two. Although the extension trials indicate extended clinical efficacy beyond two years, some MRI activity seems to reoccur [50]. Thus, an increasing proportion of patients may also develop new clinical disease activity. The consequences of further cycles of cladribine, either for disease activity or safety are at present unknown. From the prolonged lymphopenia, one would however expect that repeated treatment will lead to prolonged immunosuppression, and thereby to increased risk of infections and possibly also reduced tumor surveillance.

The therapeutic landscape for relapsing MS is likely to change during the next five years. We expect that patients will be treated more actively at an earlier time in their disease course. B cell depleting therapies [26,77,78], and if randomized clinical trials confirm the effect suggested in observational studies [78], also autologous hematopoietic stem cell transplantation, may become standard treatments. The efficacy, tolerability and convenience could still make cladribine competitive. However, data that can guide clinicians and patients beyond two years of therapy, preferentially from a long-term trial, are needed.

References


78. Sormani MP, Muraro PA, Saccardi R, et al. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Mult Scler 2017; 23: 201-204.